Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (64984)	8/5/2002 10:40:16 AM
From: SusieQ1065	Read Replies (1) \| Respond to of 208838

KLAC easing a bit...was being a tough noodle.

To: 2MAR$ who wrote (64984)	8/5/2002 10:40:47 AM
From: 2MAR$	Respond to of 208838

US FDA staff says wants input on Gilead drug risk WASHINGTON, Aug 5 (Reuters) - U.S. Food and Drug Administration staff said in a report released on Monday that Gilead Sciences Inc.'s <GILD.O> drug adefovir has a low risk of kidney toxicity in healthier hepatitis patients, but they want advisers' input on the treatment's safety in people with kidney impairment. Gilead is seeking FDA approval to market adefovir for treating patients with chronic hepatitis B, and an advisory panel will provide input on Tuesday. In two Gilead studies of patients with compensated liver disease with adequate kidney function, "it appears that the clinical benefit of adefovir 10 milligrams is substantial and the nephrotoxicity risk is low, but perhaps not zero," the report said. "The totality of evidence, however, raises some caution regarding the use of adefovir in patients with significant pre-existing renal function impairment. Therefore, we will be seeking the committee's comments on the safety of adefovir in chronic hepatitis B patients with decompensated disease and/or pre-existing renal impairment," the report said. ((Lisa Richwine, +1 202 310-5691, fax +1 202 898-8383, washington.equities.newsroom@reuters.com)) REUTERS *** end of story